Related references
Note: Only part of the references are listed.Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
Steven R. Cummings et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
M. B. Zanchetta et al.
OSTEOPOROSIS INTERNATIONAL (2018)
Bone Mineral Density Changes After 1 Year of Denosumab Discontinuation in Postmenopausal Women with Long-Term Denosumab Treatment for Osteoporosis
Albrecht Werner Popp et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
An Essential Warning
Benjamin Z. Leder
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Bisphosphonate Drug Holiday and Fracture Risk: A Population-Based Cohort Study
Annette L. Adams et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density
K. E. Naylor et al.
OSTEOPOROSIS INTERNATIONAL (2018)
THE IMPACT OF THE DURATION OF BISPHOSPHONATE DRUG HOLIDAYS ON HIP FRACTURE RATES
J. R. Curtis et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
EPIDEMIOLOGY AND POSTOPERATIVE OUTCOMES OF ATYPICAL FEMORAL FRACTURES IN OLDER ADULTS: A SYSTEMATIC REVIEW
K. S. F. Khow et al.
JOURNAL OF NUTRITION HEALTH & AGING (2017)
Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases
Athanasios D. Anastasilakis et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement
Panagiotis Anagnostis et al.
MATURITAS (2017)
Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user-only cohort study including over 60,000 alendronate users
P. A. Eiken et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Observations following discontinuation of long-term denosumab therapy
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2017)
Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk
M. A. Mignot et al.
OSTEOPOROSIS INTERNATIONAL (2017)
One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study
C. Reyes et al.
OSTEOPOROSIS INTERNATIONAL (2017)
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
Henry G. Bone et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
UK clinical guideline for the prevention and treatment of osteoporosis
J. Compston et al.
ARCHIVES OF OSTEOPOROSIS (2017)
Medication-related osteonecrosis of the jaw: a preliminary retrospective study of 130 patients with multiple myeloma
Woo-Sung Choi et al.
MAXILLOFACIAL PLASTIC AND RECONSTRUCTIVE SURGERY (2017)
Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS
Elena Tsourdi et al.
BONE (2017)
Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
Jonathan D. Adachi et al.
BMC MUSCULOSKELETAL DISORDERS (2017)
Bisphosphonate drug holidays: we reap what we sow
S. L. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Determinants of change in bone mineral density and fracture risk during bisphosphonate holiday
L. H. R. Xu et al.
OSTEOPOROSIS INTERNATIONAL (2016)
Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research
Robert A. Adler et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Mortality After Atypical Femoral Fractures: A Cohort Study
Mohammad Kharazmi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study
Bo Abrahamsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study
Bo Abrahamsen et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Risk of atypical femoral fracture during and after bisphosphonate use Full report of a nationwide study
Jorg Schilcher et al.
ACTA ORTHOPAEDICA (2015)
Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once-Yearly ZOL: HORIZON-PFT Extension Study
Richard Eastell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
The Effect of 6 Versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial
Benjamin Z. Leder et al.
LANCET (2015)
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
S. Papapoulos et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
S. Ferrari et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus
Aliya A. Khan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Residual effect after oral bisphosphonate treatment and healthy adherer effects-the Swedish adherence register analysis (SARA)
O. Strom et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties
N. Hassler et al.
OSTEOPOROSIS INTERNATIONAL (2015)
Effects of Up to 5 Years of Denosumab Treatment on Bone Histology and Histomorphometry: The FREEDOM Study Extension
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2014)
Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?
Felicia Cosman et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
A Model of BMD Changes After Alendronate Discontinuation to Guide Postalendronate BMD Monitoring
Brian McNabb et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis
E. Cairoli et al.
OSTEOPOROSIS INTERNATIONAL (2014)
Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy The FLEX Study
Douglas C. Bauer et al.
JAMA INTERNAL MEDICINE (2014)
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Postmenopausal Osteoporosis: Executive Summary of Recommendations
Nelson Watts et al.
Endocrine Practice (2013)
BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate
Brian Louis McNabb et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial
Jacques P. Brown et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2013)
The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Denosumab Compared With Ibandronate in Postmenopausal Women Previously Treated With Bisphosphonate Therapy A Randomized Open-Label Trial
Chris Recknor et al.
OBSTETRICS AND GYNECOLOGY (2013)
Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
M. R. McClung et al.
OSTEOPOROSIS INTERNATIONAL (2013)
Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
Socrates Papapoulos et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
Dennis M. Black et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Incidence of Atypical Nontraumatic Diaphyseal Fractures of the Femur
Richard M. Dell et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Bisphosphonates for Osteoporosis - Where Do We Go from Here?
Marcea Whitaker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study
P. D. Miller et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension
G. Bianchi et al.
OSTEOPOROSIS INTERNATIONAL (2012)
Risk assessment of fragility fractures: summary of NICE guidance
Silvia Rabar et al.
BRITISH MEDICAL JOURNAL (2012)
Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover
Richard Eastell et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial
Paul D. Miller et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass
Henry G. Bone et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2011)
Bisphosphonate Use and Atypical Fractures of the Femoral Shaft
Jorg Schilcher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Risedronate Reduces Intracortical Porosity in Women With Osteoporosis
Babul Borah et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Mineralization Density Distribution of Postmenopausal Osteoporotic Bone Is Restored to Normal After Long-Term Alendronate Treatment: qBEI and sSAXS Data From the Fracture Intervention Trial Long-Term Extension (FLEX)
P. Roschger et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Efficacy of Continued Alendronate for Fractures in Women With and Without Prevalent Vertebral Fracture: The FLEX Trial
Ann V. Schwartz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research
Elizabeth Shane et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure
Joan C. Lo et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2010)
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence
C. Roerholt et al.
OSTEOPOROSIS INTERNATIONAL (2009)
Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday
J. R. Curtis et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Fracture risk remains reduced one year after discontinuation of risedronate
N. B. Watts et al.
OSTEOPOROSIS INTERNATIONAL (2008)
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study
S. L. Silverman et al.
OSTEOPOROSIS INTERNATIONAL (2007)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
An estimate of the worldwide prevalence and disability associated with osteoporotic fractures
O. Johnell et al.
OSTEOPOROSIS INTERNATIONAL (2006)
Systematic review: Bisphosphonates and osteonecrosis of the jaws
Sook-Bin Woo et al.
ANNALS OF INTERNAL MEDICINE (2006)
Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment
RE Marx et al.
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2005)
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: Results from the Fracture Intervention Trial long-term extension
KE Ensrud et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic
RE Marx
JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY (2003)
Share Paper
